{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:16:12Z","timestamp":1784553372100,"version":"3.55.0"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Autologous stem cell transplantation (ASCT) is the standard treatment recommended by the National Comprehensive Cancer Network (NCCN) for newly diagnosed multiple myeloma (MM) patients who are eligible for transplantation. This procedure follows response achieved through induction therapy. The key to the success of ASCT lies in the quantity and quality of hematopoietic stem cells collected after mobilization. Studies have shown a positive correlation between the number of hematopoietic stem cells collected and the engraftment time of absolute neutrophil count (ANC) and platelet count (PLT). However, the advent of novel therapeutic agents that have significantly improved the survival of MM patients has also impacted hematopoietic stem cell mobilization, potentially delaying hematopoietic recovery, a process referred to as hematopoietic remodeling. In this paper, we will retrospectively analyze and summarise the research progress related to the effects of previous chemotherapeutic agents on hematopoietic stem cell mobilization and hematopoietic remodeling, to further improve the prognosis and quality of survival of MM patients who are eligible for transplantation.<\/jats:p>","DOI":"10.3389\/fonc.2025.1479164","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T06:59:24Z","timestamp":1739516364000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["The impact of multiple myeloma drugs treatments on autologous stem cell transplantation in the era of new drugs"],"prefix":"10.3389","volume":"15","author":[{"given":"Xixi","family":"Wan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huili","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.6004\/jnccn.2022.0002","article-title":"NCCN guidelines\u00ae Insights: multiple myeloma, version 3.2022","volume":"20","author":"Callander","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2021.05.001","article-title":"Chinese guidelines of autologous stem cell transplantation for multiple myeloma (2021)","volume":"42","year":"2021","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010972","article-title":"Autophagy prevents graft failure during murine graft-versus-host disease","volume":"8","author":"Lineburg","year":"2024","journal-title":"Blood Adv"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01973-2","article-title":"Are haematopoietic stem cell transplants stem cell transplants, is there a threshold dose of CD34-positive cells and how many are needed for rapid posttransplant granulocyte recovery","volume":"37","author":"Chen","year":"2023","journal-title":"Leukemia"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15122674","article-title":"Optimized liposomal delivery of bortezomib for advancing treatment of multiple myeloma","volume":"15","author":"Zhang","year":"2023","journal-title":"Pharmaceutics"},{"key":"B6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2147\/CMAR.S105163","article-title":"Update on the optimal use of bortezomib in the treatment of multiple myeloma","volume":"9","author":"Mohan","year":"2017","journal-title":"Cancer Manag Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.4626","article-title":"Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials","volume":"31","author":"Sonneveld","year":"2013","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-395749","article-title":"Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma","volume":"119","author":"Kumar","year":"2012","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.82","article-title":"Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005-01 trial","volume":"24","author":"Moreau","year":"2010","journal-title":"Leukemia"},{"key":"B10","doi-asserted-by":"publisher","first-page":"101070","DOI":"10.1016\/j.gendis.2023.06.037","article-title":"The role of proteasomes in tumorigenesis","volume":"11","author":"Zhou","year":"2023","journal-title":"Genes Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71125-8","article-title":"Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1\/2 study","volume":"15","author":"Kumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-10-811620","article-title":"Ixazomib, an oral proteasome inhibitor, induces rapid mobilization of hematopoietic progenitor cells in mice","volume":"131","author":"Ghobadi","year":"2018","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15020430","article-title":"Stem cell mobilization with ixazomib and G-CSF in patients with multiple myeloma","volume":"15","author":"B\u00fchler","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.1673-419X.2017.06.010","article-title":"Research progress of proteasome inhibitors in treatment of multiple myeloma","volume":"40","author":"Chen","year":"2017","journal-title":"Int J Blood Transfus Hematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-422683","article-title":"A phase 1\/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma","volume":"120","author":"Jakubowiak","year":"2012","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25435","article-title":"Phase II study of carfilzomib and dexamethasone therapy for newly diagnosed multiple myeloma","volume":"94","author":"Forsberg","year":"2019","journal-title":"Am J Hematol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.04.011","article-title":"Stem cell mobilization and autograft minimal residual disease negativity with novel induction regimens in multiple myeloma","volume":"26","author":"Bal","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B18","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3892\/ol.2024.14391","article-title":"The numerous facets of 1q21+ in multiple myeloma: Pathogenesis, clinicopathological features, prognosis and clinical progress (Review)","volume":"27","author":"Liu","year":"2024","journal-title":"Oncol Lett"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404661","article-title":"Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield","volume":"21","author":"Breitkreutz","year":"2007","journal-title":"Leukemia"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-02-0522","article-title":"Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma","volume":"106","author":"Cavo","year":"2005","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705050","article-title":"First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma","volume":"89","author":"Cavo","year":"2004","journal-title":"Haematologica"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.266841","article-title":"BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice","volume":"108","author":"Zhou","year":"2023","journal-title":"Haematologica"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.323","article-title":"Lenalidomide-induced upregulation of CXCR4 in CD34+ hematopoietic cells, a potential mechanism of decreased hematopoietic progenitor mobilization","volume":"27","author":"Li","year":"2013","journal-title":"Leukemia"},{"key":"B24","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41408-023-00816-8","article-title":"Efficacy and safety of pomalidomide, bortezomib, and dexamethasone combination chemotherapy for newly diagnosed multiple myeloma: POMACE Phase II Study","volume":"13","author":"Saj","year":"2023","journal-title":"Blood Cancer J"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/imr.12389","article-title":"Monoclonal antibodies targeting CD38 in hematological Malignancies and beyond","volume":"270","author":"van de Donk","year":"2016","journal-title":"Immunol Rev"},{"key":"B27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242115674","article-title":"Immunotherapy of multiple myeloma: current status as prologue to the future","volume":"24","author":"Abramson","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00263-0","article-title":"Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial","volume":"9","author":"Goldschmidt","year":"2022","journal-title":"Lancet Haematol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19141","article-title":"Insight into the mechanism of CD34+ cell mobilisation impairment in multiple myeloma patients treated with anti-CD38 therapy","volume":"204","author":"Venglar","year":"2024","journal-title":"Br J Haematol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01936-7","article-title":"Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible\/with no immediate intent for autologous stem cell transplantation","volume":"37","author":"Ocio","year":"2023","journal-title":"Leukemia"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-00442-4","article-title":"The nuclear export protein XPO1 - from biology to targeted therapy","volume":"18","author":"Azmi","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"4754","DOI":"10.1182\/blood-2023-180736","article-title":"Renal response of selinexor, pomalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma patients with renal impairment: A prospective, open-label, multicenter, phase 2 study","volume":"142","author":"Zhou","year":"2023","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2020.12.002","article-title":"Lymphoma-Treatment Alliance. Consensus of Chinese experts on the mobilization and collection of autologous hematopoietic stem cells in lymphoma (2020)","volume":"41","year":"2020","journal-title":"Chin J Hematol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.124818","article-title":"Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: results of a prospective phase 2 Spanish\/PETHEMA trial","volume":"100","author":"Mateos","year":"2015","journal-title":"Haematologica"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V118.21.1933.1933","article-title":"Impact of bendamustine pretreatment on stem cell mobilization and autologous stem cell transplantation in patients with multiple myeloma","volume":"118","author":"Wolfram","year":"2011","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.94","article-title":"single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy","volume":"51","author":"Martino","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-205013","article-title":"Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens","volume":"114","author":"Kumar","year":"2009","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.10.003","article-title":"Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide","volume":"18","author":"Malard","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/cancers1201017341","article-title":"HB-EGF-EGFR signaling in bone marrow endothelial cells mediates angiogenesis associated with multiple myeloma","volume":"12","author":"Rao","year":"2020","journal-title":"Cancers"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.04.010","article-title":"Prolonged lenalidomide therapy does not impact autologous peripheral blood stem cell mobilization and collection in multiple myeloma patients: A single-center retrospective analysis","volume":"27","author":"Cowan","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.07.028","article-title":"Lenalidomide-based maintenance after autologous hematopoietic stem cell transplantation for patients with high-risk multiple myeloma","volume":"28","author":"Pasvolsky","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1479164\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T06:59:31Z","timestamp":1739516371000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1479164\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,14]]},"references-count":44,"alternative-id":["10.3389\/fonc.2025.1479164"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1479164","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,14]]},"article-number":"1479164"}}